Archives: Research

Research & Insights Content Type

  • Fact Checking the NYT Fact Check on the Trump Proposal

  • A $475,000 price tag for a new cancer drug: crazy or meh?

  • US Drug Prices And R&D, Take 2: A Reply To Grabowski And Manning, And To Light

  • The Conflict Between QALYs and Well-Funded Patient Advocacy Groups

  • Remdesivir Less Expensive for “Government Programs”? Not So Fast.

    Remdesivir Less Expensive for “Government Programs”? Not So Fast.

  • Prevalence of Off-Label Use and Spending Among Patent-Protected Chemotherapies

  • Blueprints for Indication-Specific Pricing

    Blueprints for Indication-Specific Pricing

  • Pharmaceutical Products and Their Value

    Pharmaceutical Products and Their Value

  • Understanding the Rewards of Successful Drug Development: Thinking Inside the Box

  • Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection

    Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection